세계의 내분비 검사 시장(2025-2032년) : 업계 분석, 규모, 점유율, 성장, 동향, 예측

Endocrine Testing Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

US $ 4,995 ￦ 7,030,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,267,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,956,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

세계 내분비 검사 시장 규모는 2025년에 134억 달러에 달할 것으로 예상되며, 2025-2032년의 예측 기간 동안 8.2%의 연평균 복합 성장률(CAGR)로 성장하여 2032년에는 232억 달러에 달할 것으로 예측되고 있습니다.

내분비 검사 시장에는 다양한 검사 기술을 이용한 호르몬 불균형과 내분비선 질환의 진단 및 분석이 포함됩니다. 특정 내분비 관련 질병이 증가함에 따라 정확하고 신속하며 사용하기 쉬운 검사 솔루션에 대한 수요가 증가하고 있습니다.

세계의 내분비 검사 시장은 당뇨병, 갑상선 기능 항진증, 호르몬 불균형 등 내분비 질환의 급증에 의해 추진되고 있으며, 이러한 질환은 앉아서 생활하는 라이프스타일, 스트레스, 고령화에 의해 증가 추세에 있습니다. 고속대량 면역 측정법, 질량 분석법, 바이오센서 기반 방법의 통합 등 진단 기술의 진보는 검사의 정확성, 속도, 가격 경쟁력을 더욱 향상시키고 있습니다.

낙관적인 전망에도 불구하고 내분비 검사 시장은 일정한 억제요인에 직면하고 있습니다. 관련 기술의 표준화 부족으로 검사 결과의 일관성이 떨어집니다. 규제가 복잡하고, 새로운 진단 툴의 승인 프로세스에 시간이 걸리는 것도 기술 혁신과 도입의 페이스를 낮춥니다. 또한, 많은 지역에서는 숙련된 검사 인력이 부족하여 검사 서비스의 질과 신뢰성에 영향을 미치고 있습니다.

내분비 검사 시장은 맞춤형 의료 및 예측 진단으로의 전환 증가로 인한 성장 기회가 풍부합니다. 또한 헬스케어 인프라가 정비되고 환자의 의식이 높아지면서 잠재 가능성을 지니고 있습니다. 서비스가 부족한 지역에서는 내분비 검사에 대한 접근성을 높일 수 있습니다. 또한 가정 검사 키트와 원격 의료 진단의 대두로 예측 기간 동안 시장이 크게 확대될 것으로 예상됩니다.

본 보고서에서는 세계 내분비 검사 시장에 대해 조사했으며, 검사별, 기술별, 적응증별, 최종 용도별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장의 범위와 정의
• 시장 역학
• COVID-19의 영향 분석
• 예측 요인 - 관련성과 영향

제3장 부가가치 인사이트

제4장 세계 내분비 검사 시장 전망

• 주요 하이라이트
• 시장 규모의 분석과 예측
  • 과거 시장 규모 분석(2019-2024년)
  • 현재 시장 규모 분석과 예측(2025-2032년)
• 세계의 내분비 검사 시장 전망 : 검사별
  • 과거 시장 규모 분석, 검사별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 검사별(2025-2032년)
  • 시장의 매력 분석 : 검사별
• 세계의 내분비 검사 시장 전망 : 기술별
  • 과거 시장 규모 분석, 기술별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 기술별(2025-2032년)
  • 시장의 매력 분석 : 기술별
• 세계 내분비 검사 시장 전망 : 적응증별
  • 과거 시장 규모 분석, 적응증별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 적응증별(2025-2032년)
  • 시장의 매력 분석 : 적응증별
• 세계 내분비 검사 시장 전망 : 최종 용도별
  • 과거 시장 규모 분석, 최종 용도별(2019-2024년)
  • 현재 시장 규모 분석과 예측, 최종 용도별(2025-2032년)
  • 시장의 매력 분석 : 최종 용도별

제5장 세계의 내분비 검사 시장 전망 : 지역별

• 과거 시장 규모 분석, 지역별(2019-2024년)
• 현재 시장 규모 분석과 예측, 지역별(2025-2032년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아와 오세아니아
  • 중동 및 아프리카
• 시장의 매력 분석 : 지역별

제6장 북미 내분비 검사 시장 전망

제7장 유럽 내분비 검사 시장 전망

제8장 동아시아 내분비 검사 시장 전망

제9장 남아시아 및 오세아니아의 내분비 검사 시장 전망

제10장 라틴아메리카의 내분비 검사 시장 전망

제11장 중동 및 아프리카의 내분비 검사 시장 전망

제12장 경쟁 구도

• 시장 점유율 분석(2025년)
• 시장 구조
• 기업 프로파일(상세 - 개요, 재무, 전략, 최근 동향)
  • Abbott Laboratories, Inc.
  • AB Sciex Pte. Ltd.
  • Agilent Technologies, Inc.
  • bioMerieux SA
  • Bio-Rad Laboratories Inc.
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings(LabCorp)
  • Quest Diagnostics, Inc.
  • Thermo Fisher Scientific, Inc.
  • MP Biomedicals
  • Ortho-Clinical Diagnostics(QuidelOrtho Corporation)
  • Siemens Healthineers AG
  • Sysmex Corporation
  • 기타

제13장 부록

CSM

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the global Endocrine Testing Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

• Endocrine Testing Market Size (2025E): US$ 13.4 Bn
• Projected Market Value (2032F): US$ 23.2 Bn
• Global Market Growth Rate (CAGR 2025 to 2032): 8.2%

Endocrine Testing Market - Report Scope:

The endocrine testing market involves the analysis and diagnosis of hormonal imbalances and endocrine gland disorders using a range of laboratory techniques. This includes tests for thyroid function, reproductive hormones, glucose metabolism, and adrenal function, among others. With a rise in endocrine-related conditions such as diabetes, thyroid disorders, and hormonal cancers, the demand for accurate, rapid, and accessible testing solutions is escalating. Technological advancements in diagnostic methodologies, including immunoassays and tandem mass spectrometry, are revolutionizing endocrine diagnostics and improving clinical outcomes.

Market Growth Drivers:

The global endocrine testing market is being propelled by a surge in endocrine disorders, including diabetes, hyperthyroidism, and hormonal imbalances, which are on the rise due to sedentary lifestyles, stress, and aging populations. Growing awareness about early disease detection and regular health monitoring has significantly increased the volume of diagnostic testing across both developed and developing regions. Advancements in diagnostic technologies-such as the integration of high-throughput immunoassays, mass spectrometry, and biosensor-based methods-are further enhancing test precision, speed, and affordability. The expanding application of endocrine tests in home-based and point-of-care settings, fueled by patient preference for convenience and personalized healthcare, is another key driver supporting market growth.

Market Restraints:

Despite the optimistic outlook, the endocrine testing market faces certain limitations. High costs associated with advanced diagnostic platforms and specialized equipment often act as barriers in low- and middle-income regions. Moreover, variability in test accuracy and lack of standardization across laboratories can lead to inconsistent diagnostic outcomes. Regulatory complexities and the time-consuming approval process for new diagnostic tools also slow down the pace of innovation and adoption. Additionally, the shortage of skilled laboratory personnel in many regions affects the quality and reliability of testing services.

Market Opportunities:

The endocrine testing market is brimming with growth opportunities stemming from the increasing shift toward personalized medicine and predictive diagnostics. Technological innovation continues to open doors for next-generation testing solutions-such as miniaturized lab-on-a-chip devices, AI-integrated diagnostic systems, and multiplex assays-that offer enhanced sensitivity and rapid turnaround times. Emerging economies, particularly in Asia-Pacific and Latin America, present untapped potential due to their growing healthcare infrastructure and increasing patient awareness. Strategic collaborations between diagnostic companies and healthcare providers are fostering innovation and expanding access to endocrine testing in remote and underserved regions. Furthermore, the rise of at-home testing kits and telehealth diagnostics is expected to significantly broaden market reach over the forecast period.

Key Questions Answered in the Report:

• What are the primary factors driving the global endocrine testing market's growth?
• Which test types and technologies are gaining the most traction among healthcare providers?
• How are innovations in diagnostic tools impacting endocrine disease management?
• Who are the major players in the endocrine testing market, and what strategies are they employing?
• What are the regional trends and long-term projections for the endocrine testing market?

Competitive Intelligence and Business Strategy:

Leading players in the global endocrine testing market-including Abbott Laboratories, Agilent Technologies, Thermo Fisher Scientific, Quest Diagnostics, and F. Hoffmann-La Roche-are focusing on expanding their diagnostic portfolios with cutting-edge technologies. These companies are actively investing in R&D, automation, and AI-driven platforms to enhance test accuracy and workflow efficiency. Strategic acquisitions, collaborations with clinical laboratories, and partnerships with healthcare institutions are common strategies being employed to strengthen global reach. Companies are also developing patient-centric solutions, such as mobile-based testing kits and home-use devices, to cater to growing demand for decentralized diagnostics.

Companies Covered in This Report:

• Abbott Laboratories, Inc.
• AB Sciex Pte. Ltd.
• Agilent Technologies, Inc.
• bioMerieux SA
• Bio-Rad Laboratories Inc.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche Ltd.
• Laboratory Corporation of America Holdings (LabCorp)
• Quest Diagnostics, Inc.
• Thermo Fisher Scientific, Inc.

Market Segmentation:

By Test:

• Testosterone Test
• Estradiol Test
• Thyroid Stimulating Hormone (TSH) Test
• Prolactin Test
• Luteinizing Hormone (LH) Test
• Progesterone Test
• Human Chorionic Gonadotropin (hCG) Hormone Test
• Insulin Test
• Others

By Technology:

• Tandem Mass Spectrometry
• Immunoassay
• Monoclonal & Polyclonal Antibody Technologies
• Clinical Chemistry Analyzers
• Others

By Disease Indication:

• Diabetes
• Hyperthyroidism
• Menopause
• Osteoporosis
• Cancer
• Others

By End Use:

• Hospitals
• Diagnostic Laboratories
• Ambulatory Care Centers
• Home-based Tests
• Specialty Centers
• Others

By Region:

• North America
• Europe
• East Asia
• South Asia and Oceania
• Latin America
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Endocrine Testing Market Snapshot, 2025-2032
• 1.2. Market Opportunity Assessment, 2025-2032, US$ Bn
• 1.3. Key Market Trends
• 1.4. Future Market Projections
• 1.5. Premium Market Insights
• 1.6. Industry Developments and Key Market Events
• 1.7. PMR Analysis and Recommendations

2. Market Overview

• 2.1. Market Scope and Definition
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Opportunity
  • 2.2.4. Challenges
  • 2.2.5. Key Trends
• 2.3. COVID-19 Impact Analysis
• 2.4. Forecast Factors - Relevance and Impact

3. Value Added Insights

• 3.1. Value Chain Analysis
• 3.2. Test Adoption / Usage Analysis
• 3.3. Government Initiatives & Funding in Endocrine Testing
• 3.4. Key Market Players
• 3.5. Regulatory Landscape
• 3.6. PESTLE Analysis
• 3.7. Porter's Five Force Analysis
• 3.8. Consumer Behavior Analysis

4. Global Endocrine Testing Market Outlook

• 4.1. Key Highlights
  • 4.1.1. Market Size (US$ Bn) and Y-o-Y Growth
  • 4.1.2. Absolute $ Opportunity
• 4.2. Market Size (US$ Bn) Analysis and Forecast
  • 4.2.1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  • 4.2.2. Current Market Size (US$ Bn) Analysis and Forecast, 2025-2032
• 4.3. Global Endocrine Testing Market Outlook: Test
  • 4.3.1. Historical Market Size (US$ Bn) Analysis, By Test, 2019-2024
  • 4.3.2. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
    • 4.3.2.1. Testosterone Test
    • 4.3.2.2. Estradiol Test
    • 4.3.2.3. Thyroid Stimulating Hormone (TSH) Test
    • 4.3.2.4. Prolactin Test
    • 4.3.2.5. Luteinizing Hormone (LH) Test
    • 4.3.2.6. Progesterone Test
    • 4.3.2.7. Human Chorionic Gonadotropin (hCG) Hormone Test
    • 4.3.2.8. Insulin Test
    • 4.3.2.9. Others
  • 4.3.3. Market Attractiveness Analysis: Test
• 4.4. Global Endocrine Testing Market Outlook: Technology
  • 4.4.1. Historical Market Size (US$ Bn) Analysis, By Technology, 2019-2024
  • 4.4.2. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
    • 4.4.2.1. Tandem Mass Spectrometry
    • 4.4.2.2. Monoclonal & Polyclonal Antibody Technologies
    • 4.4.2.3. Clinical Chemistry
    • 4.4.2.4. Immunoassay
    • 4.4.2.5. Others
  • 4.4.3. Market Attractiveness Analysis: Technology
• 4.5. Global Endocrine Testing Market Outlook: Disease Indication
  • 4.5.1. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019-2024
  • 4.5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
    • 4.5.2.1. Diabetes
    • 4.5.2.2. Hyperthyroidism
    • 4.5.2.3. Menopause
    • 4.5.2.4. Osteoporosis
    • 4.5.2.5. Cancer
    • 4.5.2.6. Others
  • 4.5.3. Market Attractiveness Analysis: Disease Indication
• 4.6. Global Endocrine Testing Market Outlook: End-use
  • 4.6.1. Historical Market Size (US$ Bn) Analysis, By End-use, 2019-2024
  • 4.6.2. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
    • 4.6.2.1. Hospitals
    • 4.6.2.2. Diagnotics Laboratories
    • 4.6.2.3. Ambulatory Care Centers
    • 4.6.2.4. Home-based Tests
    • 4.6.2.5. Speciality Centers
    • 4.6.2.6. Others
  • 4.6.3. Market Attractiveness Analysis: End-use

5. Global Endocrine Testing Market Outlook Region

• 5.1. Historical Market Size (US$ Bn) Analysis, By Region, 2019-2024
• 5.2. Current Market Size (US$ Bn) Analysis and Forecast, By Region, 2025-2032
  • 5.2.1. North America
  • 5.2.2. Latin America
  • 5.2.3. Europe
  • 5.2.4. East Asia
  • 5.2.5. South Asia and Oceania
  • 5.2.6. Middle East & Africa
• 5.3. Market Attractiveness Analysis: Region

6. North America Endocrine Testing Market Outlook

• 6.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 6.1.1. By Country
  • 6.1.2. By Test
  • 6.1.3. By Technology
  • 6.1.4. By Disease Indication
  • 6.1.5. By End-Use
• 6.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 6.2.1. U.S.
  • 6.2.2. Canada
• 6.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 6.3.1. Testosterone Test
  • 6.3.2. Estradiol Test
  • 6.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 6.3.4. Prolactin Test
  • 6.3.5. Luteinizing Hormone (LH) Test
  • 6.3.6. Progesterone Test
  • 6.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 6.3.8. Insulin Test
  • 6.3.9. Others
• 6.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 6.4.1. Tandem Mass Spectrometry
  • 6.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 6.4.3. Clinical Chemistry
  • 6.4.4. Immunoassay
  • 6.4.5. Others
• 6.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 6.5.1. Diabetes
  • 6.5.2. Hyperthyroidism
  • 6.5.3. Menopause
  • 6.5.4. Osteoporosis
  • 6.5.5. Cancer
  • 6.5.6. Others
• 6.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 6.6.1. Hospitals
  • 6.6.2. Diagnotics Laboratories
  • 6.6.3. Ambulatory Care Centers
  • 6.6.4. Home-based Tests
  • 6.6.5. Speciality Centers
  • 6.6.6. Others
• 6.7. Market Attractiveness Analysis

7. Europe Endocrine Testing Market Outlook

• 7.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 7.1.1. By Country
  • 7.1.2. By Test
  • 7.1.3. By Technology
  • 7.1.4. By Disease Indication
  • 7.1.5. By End-use
• 7.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 7.2.1. Germany
  • 7.2.2. France
  • 7.2.3. U.K.
  • 7.2.4. Italy
  • 7.2.5. Spain
  • 7.2.6. Russia
  • 7.2.7. Rest of Europe
• 7.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 7.3.1. Testosterone Test
  • 7.3.2. Estradiol Test
  • 7.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 7.3.4. Prolactin Test
  • 7.3.5. Luteinizing Hormone (LH) Test
  • 7.3.6. Progesterone Test
  • 7.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 7.3.8. Insulin Test
  • 7.3.9. Others
• 7.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 7.4.1. Tandem Mass Spectrometry
  • 7.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 7.4.3. Clinical Chemistry
  • 7.4.4. Immunoassay
  • 7.4.5. Others
• 7.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 7.5.1. Diabetes
  • 7.5.2. Hyperthyroidism
  • 7.5.3. Menopause
  • 7.5.4. Osteoporosis
  • 7.5.5. Cancer
  • 7.5.6. Others
• 7.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 7.6.1. Hospitals
  • 7.6.2. Diagnotics Laboratories
  • 7.6.3. Ambulatory Care Centers
  • 7.6.4. Home-based Tests
  • 7.6.5. Speciality Centers
  • 7.6.6. Others
• 7.7. Market Attractiveness Analysis

8. East Asia Endocrine Testing Market Outlook

• 8.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 8.1.1. By Country
  • 8.1.2. By Test
  • 8.1.3. By Disease Indication
  • 8.1.4. By End-Use
• 8.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 8.2.1. China
  • 8.2.2. Japan
  • 8.2.3. South Korea
• 8.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 8.3.1. Testosterone Test
  • 8.3.2. Estradiol Test
  • 8.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 8.3.4. Prolactin Test
  • 8.3.5. Luteinizing Hormone (LH) Test
  • 8.3.6. Progesterone Test
  • 8.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 8.3.8. Insulin Test
  • 8.3.9. Others
• 8.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 8.4.1. Tandem Mass Spectrometry
  • 8.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 8.4.3. Clinical Chemistry
  • 8.4.4. Immunoassay
  • 8.4.5. Others
• 8.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 8.5.1. Diabetes
  • 8.5.2. Hyperthyroidism
  • 8.5.3. Menopause
  • 8.5.4. Osteoporosis
  • 8.5.5. Cancer
  • 8.5.6. Others
• 8.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 8.6.1. Hospitals
  • 8.6.2. Diagnotics Laboratories
  • 8.6.3. Ambulatory Care Centers
  • 8.6.4. Home-based Tests
  • 8.6.5. Speciality Centers
  • 8.6.6. Others
• 8.7. Market Attractiveness Analysis

9. South Asia & Oceania Endocrine Testing Market Outlook

• 9.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 9.1.1. By Country
  • 9.1.2. By Test
  • 9.1.3. By Technology
  • 9.1.4. By Disease Indication
  • 9.1.5. By End-Use
• 9.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 9.2.1. India
  • 9.2.2. Indonesia
  • 9.2.3. Thailand
  • 9.2.4. Singapore
  • 9.2.5. ANZ
  • 9.2.6. Rest of South Asia & Oceania
• 9.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 9.3.1. Testosterone Test
  • 9.3.2. Estradiol Test
  • 9.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 9.3.4. Prolactin Test
  • 9.3.5. Luteinizing Hormone (LH) Test
  • 9.3.6. Progesterone Test
  • 9.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 9.3.8. Insulin Test
  • 9.3.9. Others
• 9.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 9.4.1. Tandem Mass Spectrometry
  • 9.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 9.4.3. Clinical Chemistry
  • 9.4.4. Immunoassay
  • 9.4.5. Others
• 9.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 9.5.1. Diabetes
  • 9.5.2. Hyperthyroidism
  • 9.5.3. Menopause
  • 9.5.4. Osteoporosis
  • 9.5.5. Cancer
  • 9.5.6. Others
• 9.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 9.6.1. Hospitals
  • 9.6.2. Diagnotics Laboratories
  • 9.6.3. Ambulatory Care Centers
  • 9.6.4. Home-based Tests
  • 9.6.5. Speciality Centers
  • 9.6.6. Others
• 9.7. Market Attractiveness Analysis

10. Latin America Endocrine Testing Market Outlook

• 10.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 10.1.1. By Country
  • 10.1.2. By Test
  • 10.1.3. BY Technology
  • 10.1.4. By Disease Indication
  • 10.1.5. By End-Use
• 10.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 10.2.1. Brazil
  • 10.2.2. Mexico
  • 10.2.3. Rest of Latin America
• 10.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 10.3.1. Testosterone Test
  • 10.3.2. Estradiol Test
  • 10.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 10.3.4. Prolactin Test
  • 10.3.5. Luteinizing Hormone (LH) Test
  • 10.3.6. Progesterone Test
  • 10.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 10.3.8. Insulin Test
  • 10.3.9. Others
• 10.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 10.4.1. Tandem Mass Spectrometry
  • 10.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 10.4.3. Clinical Chemistry
  • 10.4.4. Immunoassay
  • 10.4.5. Others
• 10.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 10.5.1. Diabetes
  • 10.5.2. Hyperthyroidism
  • 10.5.3. Menopause
  • 10.5.4. Osteoporosis
  • 10.5.5. Cancer
  • 10.5.6. Others
• 10.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 10.6.1. Hospitals
  • 10.6.2. Diagnotics Laboratories
  • 10.6.3. Ambulatory Care Centers
  • 10.6.4. Home-based Tests
  • 10.6.5. Speciality Centers
  • 10.6.6. Others
• 10.7. Market Attractiveness Analysis

11. Middle East & Africa Endocrine Testing Market Outlook

• 11.1. Historical Market Size (US$ Bn) Analysis, By Market, 2019-2024
  • 11.1.1. By Country
  • 11.1.2. By Test
  • 11.1.3. By Technology
  • 11.1.4. By Disease Indication
  • 11.1.5. By End-Use
• 11.2. Current Market Size (US$ Bn) Analysis and Forecast, By Country, 2025-2032
  • 11.2.1. GCC Countries
  • 11.2.2. Egypt
  • 11.2.3. South Africa
  • 11.2.4. Northern Africa
  • 11.2.5. Rest of Middle East & Africa
• 11.3. Current Market Size (US$ Bn) Analysis and Forecast, By Test, 2025-2032
  • 11.3.1. Testosterone Test
  • 11.3.2. Estradiol Test
  • 11.3.3. Thyroid Stimulating Hormone (TSH) Test
  • 11.3.4. Prolactin Test
  • 11.3.5. Luteinizing Hormone (LH) Test
  • 11.3.6. Progesterone Test
  • 11.3.7. Human Chorionic Gonadotropin (hCG) Hormone Test
  • 11.3.8. Insulin Test
  • 11.3.9. Others
• 11.4. Current Market Size (US$ Bn) Analysis and Forecast, By Technology, 2025-2032
  • 11.4.1. Tandem Mass Spectrometry
  • 11.4.2. Monoclonal & Polyclonal Antibody Technologies
  • 11.4.3. Clinical Chemistry
  • 11.4.4. Immunoassay
  • 11.4.5. Others
• 11.5. Current Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025-2032
  • 11.5.1. Diabetes
  • 11.5.2. Hyperthyroidism
  • 11.5.3. Menopause
  • 11.5.4. Osteoporosis
  • 11.5.5. Cancer
  • 11.5.6. Others
• 11.6. Current Market Size (US$ Bn) Analysis and Forecast, By End-use, 2025-2032
  • 11.6.1. Hospitals
  • 11.6.2. Diagnotics Laboratories
  • 11.6.3. Ambulatory Care Centers
  • 11.6.4. Home-based Tests
  • 11.6.5. Speciality Centers
  • 11.6.6. Others
• 11.7. Market Attractiveness Analysis

12. Competition Landscape

• 12.1. Market Share Analysis, 2025
• 12.2. Market Structure
  • 12.2.1. Competition Intensity Mapping by Market
  • 12.2.2. Competition Dashboard
• 12.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  • 12.3.1. Abbott Laboratories, Inc.
    • 12.3.1.1. Overview
    • 12.3.1.2. Segments and Sources
    • 12.3.1.3. Key Financials
    • 12.3.1.4. Market Developments
    • 12.3.1.5. Market Strategy
  • 12.3.2. AB Sciex Pte. Ltd.
  • 12.3.3. Agilent Technologies, Inc.
  • 12.3.4. bioMerieux SA
  • 12.3.5. Bio-Rad Laboratories Inc.
  • 12.3.6. DiaSorin S.p.A.
  • 12.3.7. F. Hoffmann-La Roche Ltd.
  • 12.3.8. Laboratory Corporation of America Holdings (LabCorp)
  • 12.3.9. Quest Diagnostics, Inc.
  • 12.3.10. Thermo Fisher Scientific, Inc.
  • 12.3.11. MP Biomedicals
  • 12.3.12. Ortho-Clinical Diagnostics (QuidelOrtho Corporation)
  • 12.3.13. Siemens Healthineers AG
  • 12.3.14. Sysmex Corporation
  • 12.3.15. Others

13. Appendix

• 13.1. Research Methodology
• 13.2. Research Assumptions
• 13.3. Acronyms and Abbreviations

관련자료